Key Considerations for Stevanato Stock Investors

By Susan Ramirez • Tuesday, November 05 15:11 • Permanent Link

Stevanato marked a 15.5% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $22.39? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Stevanato belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 26.07 and an average price to book (P/B) of 3.53
The company's P/B ratio is 4.61
Stevanato has a trailing 12 month Price to Earnings (P/E) ratio of 44.8 based on its trailing 12 month price to earnings (EPS) of $0.5 per share
Its forward P/E ratio is 36.7, based on its forward earnings per share (EPS) of $0.61
STVN has a Price to Earnings Growth (PEG) ratio of 8.04, which shows the company is overvalued when we factor growth into the price to earnings calculus.
Over the last four years, Stevanato has averaged free cash flows of $108.02 Million, which on average grew 1.5%
STVN's gross profit margins have averaged 29.8 % over the last four years and during this time they had a growth rate of 3.5 % and a coefficient of variability of 24.8 %.
Stevanato has moved -26.9% over the last year compared to 30.5% for the S&P 500 -- a difference of -57.4%
STVN has an average analyst rating of buy and is -15.19% away from its mean target price of $26.4 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.